# Trial of Two Adagrasib Dosing Regimens in NSCLC With KRAS G12C Mutation (KRYSTAL 21)

> **NCT05853575** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Mirati Therapeutics Inc.** · enrollment: 200 (estimated)

## Conditions studied

- Advanced Cancer
- Metastatic Cancer
- Malignant Neoplasm of Lung

## Interventions

- **DRUG:** Adagrasib

## Key facts

- **NCT ID:** NCT05853575
- **Lead sponsor:** Mirati Therapeutics Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-02-16
- **Primary completion:** 2026-07-30
- **Final completion:** 2026-07-30
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2026-03-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05853575

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05853575, "Trial of Two Adagrasib Dosing Regimens in NSCLC With KRAS G12C Mutation (KRYSTAL 21)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05853575. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*